Finoriq research workspace
AN2 Therapeutics, Inc. (ANTX) SEC Filings & Filing Highlights
AN2 Therapeutics, Inc. also develops AN2-502998 (AN15368), an investigational, boron-based small. Review ANTX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
- Company
- AN2 Therapeutics, Inc. (ANTX)
- Ticker
- ANTX
- Market Cap
- $173.2M
- Latest Price
- $4.81
- Industry
- Biotech & Pharma
AN2 Therapeutics, Inc. (ANTX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AN2 Therapeutics, Inc. (ANTX).
| Event | Form | Date |
|---|---|---|
| AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement ofAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of | 8-K8.01 | 2026-06-04 |
| AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement ofAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of | 8-K7.01 | 2026-06-04 |
| AN2 Therapeutics, Inc.: Shareholder voteOn June 3, 2026, AN2 Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the... | 8-K5.07 | 2026-06-09 |
| AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientifi...AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights | 8-K2.02 | 2026-05-11 |
| AN2 Therapeutics, Inc.: Corporate updateOn April 9, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferie... | 8-K8.01 | 2026-04-09 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.